It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The Double CGG Codon used in the Moderna Specific Furin Cleavage site does not occur in any other Furin cleavage site in any other virus in nature. Furin cleavage sites do occur in other viruses but NOT at all in other betacoronaviruses like Covid-19 and NOT at all with the double CGG codon.
So the CGG codon in the furin cleavage site WILL have come about through Chimeric (human animal combination) gain of function research.
The researchers did a BLAST (Basic Local Alignment Search Tool) alignment search (which means they search for the gene sequence, the reverse gene sequence, the complimentary gene sequence and the reverse complimentary gene sequence) through every gene sequence in nature known to man for CTCCTCGGCGGGCACGTAG which is the 19 nucleotide sequence containing the Furin Cleavage Sequence, which also appears in Covid-19, and which is found actually in the reverse compliment form CTACGTGCCCGCCGAGGAG patented by Moderna.
US9149506B2: Modified polynucleotides encoding septin-4 – patents.google.com...
Inventor: Tirtha Chakraborty, Antonin de Fougerolles
Current Assignee: ModernaTx Inc
US9216205B2: Modified polynucleotides encoding granulysin – patents.google.com...
Inventor: Tirtha Chakraborty, Antonin de Fougerolles
Current Assignee: ModernaTx Inc
US9255129B2: Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 – patents.google.com...
Inventor: Tirtha Chakraborty, Antonin de Fougerolles
Current Assignee: ModernaTx Inc
US9301993B2: Modified polynucleotides encoding apoptosis inducing factor 1 – patents.google.com...
Inventor: Tirtha Chakraborty, Antonin de Fougerolles
Current Assignee: ModernaTx Inc
US9587003B2: Modified polynucleotides for the production of oncology-related proteins and peptides – patents.google.com...
He pointed out that Covid-19 was man made early in the pandemic and was himself assassinated by the press and the fact checkers as a result. Every single fact checker who attacked him was wrong.
Since we have proven beyond a reasonable doubt (beyond a 1 in 72 million doubt statically and with 100% certainly biochemically from the Moderna Specific Furin Cleavage Site) that Moderna made Covid-19. And since Moderna and Fauci have not admitted to having made it and have in fact covered up evidence to that effect, it may be the case that they are hiding something else as well.
The only reason that Moderna would make Covid-19 is to release it. Otherwise the entire exercise would be financially futile, commercially pointless
originally posted by: ATruGod
They are playing it off as a "quirky coincidence"...
But We all (well a lot of Us) know!
originally posted by: Ektar
I think Dr David Martin's (Patent Attorney) video showed patents pertaining to patent of virus, patent of tests & patents on jab & more & included names Fauci, Gates & others including Pfizer & Moderna & etc. Sorry cannot give a link at the moment but someone had posted those videos here on ats...maybe anonymous?
Cheers
Ektar
Nobel-Prize-winning virologist Dr. Luc Montagnier understands exactly what is happening.
He knows that this is worldwide bioterrorism.
Which is why he, along with a number of other doctors and scientists, have signed sworn affidavits alleging “crimes against humanity and attempted genocide” and submitted these affidavits to International Court
If you trust Joe Biden, Nancy Pelosi, Anthony Fauci, Rochelle Wolensky, Klaus Schwab, and Bill Gates over Nobel-Prize-winning Professor Luc Montagnier, you will not need to bother watching the video above, nor will you need to read another word of this.
originally posted by: Archivalist
If we hold Moderna to the same standard that Monsanto holds farmers, then they need to be crucified in court for this.
Monsanto patented genetic code ends up in your crop
Monsanto sues you
Ergo, by the same legal railwork that allows Monsanto to win these cases, Moderna is liable for Covid.
This is primed to go up to the Supreme Court if any lawyer has the balls to do this. The risk of assassination is very high.
originally posted by: MichiganSwampBuck
With this information laid bare before us, what should our reaction be?
Anything online is subject to censorship and highly scrutinized.
What can be done except put together the information in a pamphlet and hand it out on the street corner? Just like a Jehovah's Witness or Hare Krishna might do and I'll bet you get the same reaction from the public.
originally posted by: detroitnative
a reply to: v1rtu0s0
And the Vaccine Junkies are still saying that everyone should be vaccinated and boosted. You have to be an insane lunatic to still think the vaccine is or was a good idea.
I am one of 4 people who didn't get it in my office. They were threatening that we would have to test daily, ect.. Then all of a sudden there was no mention of mandates, masks or vaccines. But now we have a War in the Ukraine. pfft..
2005–2009: Preface
In 2005, Derrick Rossi, a 39-year-old postdoctoral fellow in stem cell biology at Stanford University, studied a paper by Hungarian biochemist Katalin Karikó on RNA-mediated immune activation and her co-discovery with American immunologist Drew Weissman of the nucleoside modifications that suppress the immunogenicity of RNA.[6][7]
In 2007, Rossi set out to build on their findings as a new assistant professor at Harvard Medical School running his own lab.[6]
Rossi developed a method of modifying mRNA first via transfection into human cells, then dedifferentiating it into bone marrow stem cells which could then be further differentiated into desired target cell types.[8][9]
2010–2016
In 2010, Rossi approached fellow Harvard University faculty member Timothy A. Springer, who solicited co-investment from Kenneth R. Chien, Bob Langer, and Venture Studio Flagship Ventures, run by Noubar Afeyan.[9][10] Together they founded "ModeRNA Therapeutics", named from the combined terms "modified" and "RNA" that just happens to contain "modern".[11]
In 2011, Afeyan, the largest shareholder of Moderna, hired Stéphane Bancel, previously an executive at BioMérieux and Eli Lilly and Company, as CEO.[9][12] Within 2 years of its founding, the company reached a unicorn valuation.[13] In December 2012, the company raised $40 million.[14]
In March 2013, Moderna and AstraZeneca signed a five-year exclusive option agreement to discover, develop, and commercialize mRNA for treatments in the therapeutic areas of cardiovascular, metabolic, and renal diseases, and selected targets for cancer.[12][15][16] The agreement included a $240 million upfront payment to Moderna, "one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials".[15] Only one candidate from this partnership has passed Phase I trials, AZD8601, a regenerative medicine treatment which encodes vascular endothelial growth factor A to stimulate blood vessel growth for patients with myocardial ischemia undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function.[a]
In September 2013, the company reported that it was able to improve heart function in mice and enhance their long-term survival with a "redirection of their [stem cell] differentiation toward cardiovascular cell types" in a significant step for regenerative medicine.[18][19]
In October 2013, the company was awarded up to $25 million by DARPA to develop messenger RNA therapeutics.[20]
In November 2013, the company raised $110 million of equity financing.[18]
In January 2014, Alexion Pharmaceuticals paid Moderna $100 million for ten product options to develop rare disease treatments, including for Crigler-Najjar syndrome, using Moderna's mRNA therapeutics platform.[21] Although CEO Bancel expected the platform to enter human trials in 2016, the program with Alexion was scrapped in January 2017 after animal trials showed that Moderna's treatment would never be safe enough for humans.[12][13]
2017
In November 2017, Moderna employees safely tested mRNA technology in Sprague-Dawley rats and cynomolgus monkeys at the Montreal and Sherbrooke facilities of Charles River Laboratories. They found, among other things, that "mRNA is a labile biological molecule and therefore requires the use of protective delivery systems to effectively harness its potential," as the mRNA spread beyond the injection site and was found in the liver, spleen, bone marrow and heart.[22]
2018–2019: Initial public offering
In 2018, the company rebranded as "Moderna Inc." and further increased its portfolio of vaccine development.[23]
In July 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical and clinical work.[24][25]
In December 2018, Moderna became a public company via the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share).[26][27][28]
Through year-end 2019, Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019.[29]
2020–2021: COVID-19 vaccine
Main articles: Moderna COVID-19 vaccine and MRNA-1283
See also: COVID-19 vaccine and RNA vaccine
The Moderna COVID‑19 vaccine, codenamed mRNA-1273 and sold under the brand name Spikevax, is a COVID-19 vaccine developed by Moderna, the US National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
In March 2020, the Food and Drug Administration (FDA) approved clinical trials for the Moderna vaccine candidate, with Moderna receiving investment of $483 million from Operation Warp Speed.[23] Moncef Slaoui, then a member of the board of directors of Moderna, was appointed head scientist for the Operation Warp Speed project.[23]
In July 2020, the Moderna COVID-19 vaccine candidate was shown to be immunogenic in a Phase I trial involving 45 volunteers aged 18–55 years.[30]
On November 16, 2020, an interim analysis of Phase III clinical trials, which involved over 30,000 patients, showed that the Moderna COVID-19 vaccine candidate was 94.1% effective in preventing COVID-19 with only minor flu-like side effects.[31] The trials were completed on November 30, 2020, which confirmed the interim results and that the vaccine candidate was 100% effective in preventing severe cases of COVID-19.[32]
On December 18, 2020, mRNA-1273 was issued an emergency use authorization (EUA) in the United States.[33][34][35][23] On December 23, 2020, it was authorized for use in Canada.[36][37][38] On January 6, 2021, it was authorized for use in the European Union.[39][40] On January 8, 2021, mRNA-1273 was authorized for use in the United Kingdom.[41]
Moderna partnered with Swiss contract manufacturer Lonza Group to produce as much as 1 billion doses in 2021.[42]
On March 15, 2021, Phase I clinical trials began for mRNA-1283, primarily intended to be used as a COVID-19 vaccine booster.[43]
On June 25, 2021, the Food and Drug Administration added a warning about rare cases of myocarditis, a heart inflammation, associated with both Moderna and Pfizer/BioNTech vaccines to their respective fact sheets.[44][45]
On August 17, 2021, the United Kingdom's Medicines and Healthcare products Regulatory Agency approved Moderna's Covid vaccine for use in children aged 12 to 17 years.[46][47][48]
Early life and education
[icon]
This section needs expansion. You can help by adding to it. (January 2022)
Robert Malone received his BSc in biochemistry from the University of California, Davis in 1984, his MSc in biology from the University of California, San Diego in 1988, and his MD from Northwestern University Feinberg School of Medicine in 1991.[7][8][9] He attended Harvard Medical School for a year-long postdoctoral studies program.[10]
Career
In the late 1980s, while a graduate student researcher at the Salk Institute for Biological Studies in San Diego, California, Malone conducted studies on messenger ribonucleic acid (mRNA) technology, discovering in a landmark experiment that it was possible to transfer mRNA protected by a liposome into cultured cells to signal the information needed for the production of proteins.[3][11][4] In 1987, Malone performed experiments on the transfection of RNA into human, rat, mouse, Xenopus, and Drosophila cells, work which was published in 1989.[3][12] A follow-up study also published in 1989 found that frog embryos absorbed such mRNA. A 1990 paper, in collaboration with Jon A. Wolff, Dennis A. Carson, and others, first suggested the possibility of synthesizing mRNA in a laboratory to trigger the production of a desired protein.[13] These studies are recognized as among the earliest steps towards mRNA vaccine development.[3][14][15][16] Malone claims to be the inventor of mRNA vaccines, and while Stan Gromkowski, an early mRNA vaccine researcher and cellular immunologist, views Malone as "an underappreciated pioneer" who could be in contention to win a Nobel Prize for his work,[1] credit for the distinction is more often given to later advancements by Katalin Karikó and Drew Weissman[17][3] or Moderna co-founder Derrick Rossi,[11][18][19] and was ultimately the result of the contributions of hundreds of researchers, including Malone.[20]
Malone has served as director of clinical affairs for Avancer Group, assistant professor at the University of Maryland, Baltimore school of medicine, and an adjunct associate professor of biotechnology at Kennesaw State University.[21] He was CEO and co-founder of Atheric Pharmaceutical,[22] which in 2016 was contracted by the U.S. Army Medical Research Institute of Infectious Diseases to assist in the development of a treatment for the Zika virus by evaluating the efficacy of existing drugs.[23][24][25][26] Until 2020, Malone was chief medical officer at Alchem Laboratories, a Florida pharmaceutical company.[27]